ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Biotechnological approach to a new foot-and-mouth disease virus vaccine | JoVE Visualize

Home
Research Domains
Engineering

Biotechnological approach to a new foot-and-mouth disease virus vaccine

Biotechnology & Genetic Engineering Reviews|January 1, 1984

View abstract on PubMed

Summary

Developing a safe Foot-and-Mouth Disease Virus (FMDV) vaccine is possible using the VP1 protein. Biotechnology enables efficient production of VP1 for subunit vaccines, offering a promising alternative to traditional methods.

Area of Science:

Veterinary Virology
Vaccine Development
Biotechnology

Background:

Foot-and-Mouth Disease Virus (FMDV) poses a significant threat to livestock.
Traditional FMDV vaccines face challenges due to viral antigenic drift.
The VP1 protein has been identified as the key immunogenic component of FMDV.

Purpose of the Study:

To explore the development of a safe and effective FMDV subunit vaccine.
To leverage biotechnology for the production of FMDV antigens.
To investigate strategies for overcoming FMDV antigenic variability in vaccine design.

Main Methods:

Utilizing recombinant DNA technology to produce the VP1 protein in bacteria.
Analyzing amino acid sequences to identify conserved antigenic domains.
Synthesizing peptides corresponding to critical antigenic determinants.
Evaluating experimental vaccines based on genetically engineered or chemically synthesized VP1.

Main Results:

Biotechnological production of VP1 allows for large-scale, rapid manufacturing.
Identification of antigenic domains aids in understanding viral variability.
Experimental vaccines using VP1 antigens show encouraging results against homologous virus.
Alternative vaccine strategies based on conserved antigenic sites are being explored.

Conclusions:

Subunit vaccines based on the FMDV VP1 protein are a viable and safe alternative.
Biotechnology offers efficient methods for producing FMDV vaccine components.
Addressing FMDV antigenic drift through conserved epitopes is crucial for broad protection.

Biomedical Engineering

Biotechnological Approach To A New Foot-and-mouth Disease Virus Vaccine